article thumbnail

Universal Design Principles: The Importance of Equitable Use for Everyone

Perficient: Drug Development

For instance, a pharmacy with counters at accessible heights benefits wheelchair users, older adults, and even children. For example, large, clear signage in pharmacies helps individuals with visual impairments, non-native speakers, and people navigating the space for the first time.

article thumbnail

What is Special about September 24, 2023 for the UDI System?

FDA Law Blog: Biosimilars

Such codes need to be placed on device labels and packages to allow devices to be easily identified and tracked throughout their lifecycle, except where the rule provided for an exception or alternative. Once the device is required to bear a UDI, any NHRIC and NDC codes will no longer be permitted on the device label or device packaging.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Educating Patients about Generic Drugs: Strategies for Success

Drug Patent Watch

When educating elderly patients: Be patient and take extra time to explain concepts Use larger print materials for easier reading Address concerns about changes in pill appearance or packaging Communicating with Young Adults Younger patients may be more open to generic drugs but might lack knowledge about how they work. A: In most cases, yes.

Drugs 70
article thumbnail

The Ultimate Guide to Help You Understand and Treat Urticaria (Hives)

Olympian Clinical Research

Be sure to follow the instructions on the package and only use the medication as directed. You can find aloe vera gel at most pharmacies or supermarkets. Some of the ways you may do this are by: Use Anti-Itch Medication. Over-the-counter antihistamines may relieve the itchiness and swelling associated with hives.

article thumbnail

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

The Pharma Data

These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, ” Products”), (..)

article thumbnail

RECOVERY Trial Data Monitoring Committee Recommends Continuing Evaluation of REGN-COV2 in All Hospitalized Patients

The Pharma Data

Food and Drug Administration (“FDA”) will grant an Emergency Use Authorization (“EUA”) for REGN-COV2 and, if an EUA is granted, the scope and terms of such EUA and how long such EUA would remain in effect for REGN-COV2; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s product candidates (such (..)

article thumbnail

REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements

The Pharma Data

Food and Drug Administration (“FDA”) with respect to a potential Emergency Use Authorization (“EUA”) for REGN-COV2, and possible regulatory approval of REGN-COV2; whether the FDA will grant an EUA for REGN-COV2 and, if an EUA is granted, the scope and terms of such EUA and how long such EUA would remain in effect for REGN-COV2; (..)